Citation Impact
Citing Papers
Preferential Generation of Follicular B Helper T Cells from Foxp3 + T Cells in Gut Peyer's Patches
2009 StandoutScienceNobel
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program
2007 StandoutNobel
Modulation of immune cell reactivity with cis -binding Siglec agonists
2021 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
2010 StandoutNobel
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
2010
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
2014 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease
2007 Standout
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
2014 StandoutNature
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
2000
Early Clostridium difficile Infection during Allogeneic Hematopoietic Stem Cell Transplantation
2014
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step
2009
Viral Infection in the Renal Transplant Recipient
2005
Dendritic cells: versatile controllers of the immune system
2007 StandoutNobel
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
2017
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Headache related to brain tumors
2006
Follicular B helper T cells in antibody responses and autoimmunity
2005
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
2005
Radioimmunotherapy of non-Hodgkin’s lymphoma: a critical appraisal
2005
Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins
2008
Graft-versus-host disease
2009 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
2007
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
2011
Malignant Gliomas in Adults
2008 Standout
CD22 as a target of passive immunotherapy
2003
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection
2010
Monoclonal antibodies as therapeutic agents for cancer
2004
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Immunotherapy: past, present and future
2003
IgG4-related disease
2014 Standout
The Epidemiology of Myelodysplastic Syndromes
2010
Ligand-targeted therapeutics in anticancer therapy
2002
The DNA methylome
2010
Infection in Solid-Organ Transplant Recipients
2007 Standout
Gold Nanorods: From Synthesis and Properties to Biological and Biomedical Applications
2009 Standout
Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography
2006
Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors
2009
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Monoclonal antibodies for cancer immunotherapy
2009
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
2009
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy
2010
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
2014
Carbon quantum dots and their applications
2014 Standout
Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
2003
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice
2012 StandoutNobel
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Multiple Sclerosis
2018 Standout
Advances in targeted therapeutic agents
2010
Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial
2003
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell–dependent immunity to B-cell lymphoma
2003
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
2009
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Spermidine in health and disease
2018 StandoutScience
Monoclonal Antibody Therapy for Cancer
2003
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
2003
Antibody−Dendrimer Conjugates: The Number, Not the Size of the Dendrimers, Determines the Immunoreactivity
2008
Cancer Genome Landscapes
2013 StandoutScience
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Immune Regulation of Cancer
2010
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Regulatory roles of IL-10–producing human follicular T cells
2019 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Immune Therapy for Cancer
2008
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
2002
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Innate or Adaptive Immunity? The Example of Natural Killer Cells
2011 StandoutScience
Works of Brad Pohlman being referenced
Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
2012
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy
1998
Yttrium 90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma
2004
Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors
2007
Biologic predictors in follicular lymphoma: Importance of markers of immune response
2007
Radioimmunotherapy for non-Hodgkin’s lymphoma: A review for radiation oncologists
2006
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
2004
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
2007
High prevalence of diarrhea but infrequency of documented Clostridium difficile in autologous peripheral blood progenitor cell transplant recipients
2000
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection
2004
Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies
2007
The Ratio of FOXP3+ Regulatory T Cells to Granzyme B+ Cytotoxic T/NK Cells Predicts Prognosis in Classical Hodgkin Lymphoma and Is Independent of bcl-2 and MAL Expression
2007
Review of clinical radioimmunotherapy
2006
Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?
2009
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
2002
Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).
2006
Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome
2005
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
2006
LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab
2007
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group
2000